###begin article-title 0
###xml 64 65 61 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
Transforming Growth Factor-beta Suppresses the Activation of CD8+ T-Cells When Naive but Promotes Their Survival and Function Once Antigen Experienced
###end article-title 0
###begin p 1
###xml 44 61 44 61 <email xmlns:xlink="http://www.w3.org/1999/xlink">matthias@liai.org</email>
Corresponding author: Matthias von Herrath, matthias@liai.org
###end p 1
###begin p 2
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See  for details.
###end p 2
###begin p 3
###xml 0 10 0 10 <bold xmlns:xlink="http://www.w3.org/1999/xlink">OBJECTIVE&#8212;</bold>
###xml 204 205 198 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
OBJECTIVE-Transforming growth factor-beta (TGF-beta) can exhibit strong immune suppression but has also been shown to promote T-cell growth. We investigated the differential effect of this cytokine on CD8+ T-cells in autoimmunity and antiviral immunity.
###end p 3
###begin p 4
###xml 0 28 0 28 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESEARCH DESIGN AND METHODS&#8212;</bold>
###xml 36 41 <span type="species:ncbi:10090">mouse</span>
RESEARCH DESIGN AND METHODS-We used mouse models for virally induced type 1 diabetes in conjunction with transgenic systems enabling manipulation of TGF-beta expression or signaling in vivo.
###end p 4
###begin p 5
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESULTS&#8212;</bold>
###xml 127 128 124 125 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 312 313 306 307 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 451 452 442 443 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 579 580 570 571 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 635 636 623 624 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 892 893 877 878 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 963 964 944 945 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 692 726 <span type="species:ncbi:11623">lymphocytic choriomeningitis virus</span>
RESULTS-Surprisingly, when expressed selectively in the pancreas, TGF-beta reduced apoptosis of differentiated autoreactive CD8+ T-cells, favoring their expansion and infiltration of the islets. These results pointed to drastically opposite roles of TGF-beta on naive compared with antigen-experienced/memory CD8+ T-cells. Indeed, in the absence of functional TGF-beta signaling in T-cells, fast-onset type 1 diabetes caused by activation of naive CD8+ T-cells occurred faster, whereas slow-onset disease depending on accumulation and activation of antigen-experienced/memory CD8+ T-cells was decreased. TGF-beta receptor-deficient CD8+ T-cells showed enhanced activation and expansion after lymphocytic choriomeningitis virus infection in vivo but were more prone to apoptosis once antigen experienced and failed to survive as functional memory cells. In vitro, TGF-beta suppressed naive CD8+ T-cell activation and gamma-interferon production, whereas memory CD8+ T-cells stimulated in the presence of TGF-beta showed enhanced survival and increased production of interleukin-17 in conjunction with gamma-interferon.
###end p 5
###begin p 6
###xml 0 12 0 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CONCLUSIONS&#8212;</bold>
###xml 41 42 38 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
CONCLUSIONS-The effect of TGF-beta on CD8+ T-cells is dependent on their differentiation status and activation history. These results highlight a novel aspect of the pleiotropic nature of TGF-beta and have implications for the design of immune therapies involving this cytokine.
###end p 6
###begin p 7
Published ahead of print at  on 8 August 2008.
###end p 7
###begin p 8
C.M.F. and A.E.J. contributed equally to this study.
###end p 8
###begin p 9
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 9
###begin p 10
###xml 283 284 274 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 484 485 469 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 486 487 471 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 672 673 654 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 674 675 656 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 753 754 732 733 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 782 783 761 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 921 922 897 898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 923 924 899 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 925 926 901 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 319 323 <span type="species:ncbi:10090">mice</span>
Transforming growth factor beta1 (TGF-beta) is a multifunctional cytokine that acts on a wide assortment of cell types regulating both cell growth and differentiation. TGF-beta can have potent inhibitory effects on T-cell proliferation, cytokine production, and cytolytic functions (1). In addition, the development of mice lacking functional TGF-beta receptor signaling specifically in T-cells has illustrated the important role of TGF-beta in maintaining normal immune homeostasis (2,3). However, despite the clear inhibitory effects of TGF-beta on T-cells, several studies also demonstrate that this cytokine can in certain circumstances enhance the growth of T-cells (4-6). For example, TGF-beta, along with interleukin (IL)-2, enables prolonged CD4+ T-cell effector expansion (4). The enhanced accumulation of T-cells cultured in TGF-beta may be at least in part caused by the antiapoptotic effect of this cytokine (4,5,7).
###end p 10
###begin p 11
###xml 75 76 72 73 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 81 82 78 79 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 184 185 181 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 186 187 183 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 188 189 185 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 453 454 444 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 572 574 560 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 575 577 563 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 712 714 694 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 715 717 697 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 810 812 789 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 904 906 879 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 1112 1114 1084 1086 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 1177 1178 1146 1147 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
The diverse effects of TGF-beta are dependent on T-cell type (Th1, Th2, CD4+, CD8+), differentiation status (naive versus memory), and microenvironment (cytokine and cellular milieu) (4,6,8). Because of its ability to inhibit T-cell responses, many studies have evaluated TGF-beta as a potential therapeutic agent for treating autoimmune diseases like type 1 diabetes. Indeed, systemic administration of TGF-beta was shown to protect from this disease (9). In addition, TGF-beta is produced on therapy or induction of regulatory T-cells that protect from type 1 diabetes (10,11). Transgenic expression of TGF-beta in pancreatic beta-cells was also found to prevent diabetes in the NOD model for type 1 diabetes (12-14). However, in other diabetes models, TGF-beta expressed in the islets either had no effect (15) or resulted in spontaneous disease when expressed along with tumor necrosis factor-alpha (16). A superimposed problem in some of these previous studies was that constitutive expression of TGF-beta led to significant fibrosis in the islets, which made interpretation of the findings more difficult (15). Overall, little is known about the effect of TGF-beta on CD8+ T-cells in type 1 diabetes.
###end p 11
###begin p 12
###xml 45 46 42 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 214 215 211 212 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 424 426 415 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 427 429 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 730 732 715 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
###xml 917 918 902 903 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1235 1236 1220 1221 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1381 1382 1366 1367 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 148 153 <span type="species:ncbi:10090">mouse</span>
###xml 370 374 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 375 380 <span type="species:ncbi:10090">mouse</span>
###xml 590 594 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 595 599 <span type="species:ncbi:10090">mice</span>
###xml 628 632 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 750 754 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 792 796 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 820 824 <span type="species:ncbi:10090">mice</span>
###xml 895 899 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 1006 1010 <span type="species:ncbi:10090">mice</span>
###xml 1049 1053 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 1132 1136 <span type="species:ncbi:10090">mice</span>
###xml 1138 1142 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
Here, we examined the role of TGF-beta on CD8+ T-cell effector functions in the pathogenesis of virally induced type 1 diabetes by using transgenic mouse models allowing for precise tracking of the autoreactive CD8+ T-cell response, selective expression of TGF-beta in the pancreatic islets, or elimination of functional TGF-beta receptor expression on T-cells. The RIP-LCMV mouse model for virally induced type 1 diabetes (17,18) is well suited to address the role played by TGF-beta in autoimmunity while at the same time evaluating the effect of this cytokine on antiviral immunity. RIP-LCMV mice express viral antigens from LCMV under the control of RIP selectively on pancreatic beta-cells and, in some lines, in the thymus (19). In C57BL/6 RIP-LCMV-glycoprotein (RIP-GP) and BALB/c RIP-LCMV-nucleoprotein (RIP-NP) mice, which do not express the viral antigen in the thymus, infection with LCMV induces rapid CD8+ T-cell-dependent diabetes. In contrast, disease develops more slowly in C57BL/6 RIP-NP mice as a consequence of expression of the LCMV nucleoprotein not only in the pancreas but also the thymus. In C57BL/6 RIP-NP mice, LCMV infection is cleared before insulitis and autoimmunity fully develop. In this model, the CD8+ T-cells infiltrating the islets are of the memory effector phenotype, whereas in the more rapid diabetes models, primary activation of naive CD8+ T-cells in lymphoid organs in the periphery on viral infection is responsible for beta-cell destruction.
###end p 12
###begin p 13
###xml 227 229 218 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 525 527 510 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 528 530 513 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 745 746 721 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 934 935 901 902 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1071 1072 1035 1036 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 37 41 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 42 46 <span type="species:ncbi:10090">mice</span>
###xml 60 65 <span type="species:ncbi:10090">mouse</span>
###xml 560 575 <span type="species:ncbi:10090">transgenic mice</span>
###xml 760 775 <span type="species:ncbi:10090">transgenic mice</span>
###xml 800 804 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
In the current study, we crossed RIP-LCMV mice to different mouse trains which enabled control over TGF-beta expression or signaling. First, we used the tetracycline-dependent TGF-beta gene transcription system (TTA/TGF-beta) (14), thereby allowing for TGF-beta expression selectively in the islets to be turned on and off at will. This strategy appeared necessary in light of earlier studies showing that constitutive expression of TGF-beta in islets leads to profound fibrosis, making immunologic interpretation difficult (12,13). Second, we used dnTGFbetaR transgenic mice whose T-cells lack expression of the receptor for TGF-beta as a result of transgenic expression of a dominant-negative form of TGF-beta receptor selectively in T-cells (2). The double-transgenic mice generated using the RIP-LCMV and TTA/TGF-beta or dnTGFbetaR strains constituted ideal models to address the role of TGF-beta in autoreactive and antiviral CD8+ T-cell responses in vivo. Our results highlight a differential effect of TGF-beta on naive compared with antigen-experienced/memory CD8+ T-cells and their function in virally induced type 1 diabetes.
###end p 13
###begin title 14
RESEARCH DESIGN AND METHODS
###end title 14
###begin p 15
###xml 142 144 133 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 300 301 285 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 366 368 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 369 371 354 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
###xml 443 445 428 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
###xml 484 485 469 470 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 835 837 820 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 13 17 <span type="species:ncbi:10090">mice</span>
###xml 170 174 <span type="species:ncbi:10090">mice</span>
###xml 189 193 <span type="species:ncbi:10090">mice</span>
###xml 251 255 <span type="species:ncbi:10090">mice</span>
###xml 268 272 <span type="species:ncbi:10090">mice</span>
###xml 411 415 <span type="species:ncbi:10090">mice</span>
###xml 499 503 <span type="species:ncbi:10090">mice</span>
###xml 589 593 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 594 598 <span type="species:ncbi:10090">mice</span>
###xml 658 662 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
TTA/TGF-beta mice expressing TGF-beta selectively on beta-cells on removal of doxycycline from the diet were generated on the NOD background (14) and crossed with BALB/c mice. TTA/TGF-beta mice on the BALB/c background were crossed with BALB/c RIP-NP mice. dnTGFbetaR mice on the C57BL/6 background (2) were crossed onto the C57BL/6 RIP-GP and C57BL/6 RIP-NP lines (18,19). Naive T-cell receptor transgenic P14 mice on the C57BL/6 background (20) were used to obtain GP33-specific CD8+ T-cells. All mice were 6-9 weeks old when used in experiments. In all experiments using transgenic RIP-LCMV mice for diabetes studies, transgene-positive and -negative RIP-LCMV littermates were used. Blood glucose was monitored using the OneTouch Ultra system (LifeScan) at weekly intervals. Diabetes was defined as blood glucose values >300 mg/dl (21).
###end p 15
###begin title 16
Virus and peptides.
###end title 16
###begin p 17
###xml 26 28 26 28 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 225 226 225 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 284 285 284 285 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 312 319 312 319 <sub xmlns:xlink="http://www.w3.org/1999/xlink">118&#8211;126</sub>
###xml 348 349 348 349 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 376 381 376 381 <sub xmlns:xlink="http://www.w3.org/1999/xlink">33&#8211;41</sub>
###xml 460 462 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 0 4 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 182 186 <span type="species:ncbi:10090">Mice</span>
###xml 297 301 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 361 365 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
LCMV Armstrong clone 53b (22) was used throughout all experiments. Virus was plaque-purified three times on Vero cells, and stocks were prepared by a single passage on BHK-21 cells. Mice were infected with a single dose of 105 plaque-forming units intraperitoneally. The dominant H2-ld-restricted LCMV epitope NP118-126 (NP118) or the dominant H2-Db-restricted LCMV epitope GP33-41 (GP33) (LIAI Peptide Core Facility) were used for viral and diabetes studies (23).
###end p 17
###begin title 18
Immunohistochemistry.
###end title 18
###begin p 19
###xml 267 268 263 264 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 269 270 265 266 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 455 461 <span type="species:ncbi:9986">rabbit</span>
###xml 467 472 <span type="species:ncbi:10090">mouse</span>
###xml 532 538 <span type="species:ncbi:9986">rabbit</span>
###xml 854 857 <span type="species:ncbi:10116">rat</span>
###xml 863 868 <span type="species:ncbi:10090">mouse</span>
###xml 917 920 <span type="species:ncbi:10116">rat</span>
For all stainings, 6- to 10-mum tissue sections were cut using a cryomicrotome and sialin-coated Superfrost Plus slides (Fisher Scientific). For TGF-beta staining, tissues were fixed in 4% formalin and paraffin embedded. Sections were then rehydrated, quenched with H2O2 to block endogenous peroxidase, and treated in a microwave oven in the presence of citrate buffer (10 mmol/l, pH 6.0) for 10 min (two cycles of 5 min each). TGF-beta was stained using rabbit anti-mouse TGF-beta1 (Santa Cruz Biotechnology) and biotinylated anti-rabbit secondary antibody (Vector Laboratories). For CD8 staining, tissues were immersed in Tissue-Tek O.C.T. (Bayer) and snap-frozen on dry ice. Sections were then fixed with 90% ethanol at -20degreesC and washed with PBS, and avidin/biotin was blocked using a commercial kit (Vector Laboratories). CD8 was stained using rat anti-mouse CD8alpha (BD Biosciences) and biotinylated anti-rat secondary antibody (Vector Laboratories) for 60 min each. For both TGF-beta and CD8 staining, the color reaction was performed by sequential incubation with avidin-peroxidase conjugate (Vector Laboratories) and diaminobenzidine-hydrogen peroxide. Terminal deoxynucleotidyl transferase biotin-dUTP nick-end labeling (TUNEL) was performed using an ApopTag kit (Intergen Company).
###end p 19
###begin title 20
Isolation of lymphocytes from the pancreas.
###end title 20
###begin p 21
###xml 167 171 <span type="species:ncbi:10090">mice</span>
Pancreata were collected and pancreatic draining lymph nodes removed. Pancreata were mechanically disrupted using glass slides. Material was pooled from three to four mice, and lymphocytes were isolated using a lympholyte sucrose gradient (CedarLane).
###end p 21
###begin title 22
Flow cytometry.
###end title 22
###begin p 23
###xml 118 119 118 119 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 133 134 133 134 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 189 191 189 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r24">24</xref>
Fluorescently labeled monoclonal antibodies were obtained from BD Biosciences, eBioscience, BioLegend, or Caltag. H2-ld/NP118 or H2-Db/GP33 tetramers were produced as previously described (24). Cells were processed on a LSRII or FACScalibur (BD Biosciences) and results analyzed using FlowJo (Tree Star). For intracellular staining, single-cell suspensions were stimulated as described, stained for surface molecules, fixed in 2% paraformaldehyde (Sigma-Aldrich), permeabilized, and stained for intracellular cytokines in buffer containing 0.05% saponin (Sigma-Aldrich). Annexin V staining was performed using a commercial kit (BD Biosciences).
###end p 23
###begin title 24
Cell culture.
###end title 24
###begin p 25
###xml 487 488 480 481 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 647 648 639 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 863 864 855 856 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 99 103 <span type="species:ncbi:10090">mice</span>
###xml 400 404 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 992 997 <span type="species:ncbi:9606">human</span>
For dendritic cell purification, spleens and mesenteric lymph nodes were pooled from naive C57BL/6 mice and disrupted using collagenase D (Roche) in Hanks' balanced salt solution media (Invitrogen). Dendritic cells were then purified by magnetic separation using anti-CD11c MACS microbeads, washed, and loaded for 2 h at 37degreesC with 3 mug/ml GP33 peptide. Alternatively, cells were infected with LCMV at multiplicity of infection (MOI) of 0.1 on start of culture. Naive or memory CD8+ T-cells were purified by magnetic separation using anti-CD8 MACS microbeads. T-cells were labeled for 10 min with 5 mumol/l 5(6)-carboxyfluorescein diacetate N-succinimidyl ester (CFSE; Sigma-Aldrich), washed, and cultured with GP33-loaded dendritic cells (at a ratio of 1 dendritic cell to 3 T-cells) in RPMI 1640 (Invitrogen) supplemented with 10% FCS (Hyclone), 2 mmol/l l-glutamine (Sigma-Aldrich), and 50 mumol/l 2-mercaptoethanol (Sigma-Aldrich), in the presence or absence of 3 ng/ml recombinant human TGF-beta1 (R&D systems). Then, 3 days later, Brefeldin A was added to the wells for 4 h, and cells were stained for intracellular cytokines.
###end p 25
###begin title 26
RNase protection assay.
###end title 26
###begin p 27
###xml 31 32 31 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 212 214 211 213 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
Total RNA was isolated from CD8+ T-cells with chloroform using TRI reagent (Molecular Research Center), precipitated with isopropanol, and washed with ethanol. We used 5 mug of total RNA for hybridization with a 32P-UTP-labeled multitemplate obtained from a commercial kit (RiboQuant, mCYC-1; BD Biosciences). RNase protection assay was carried out according to the manufacturer's guidelines. The resulting analytical acrylamide gel was scanned using a Storm 860 PhosphorImaging system (Molecular Dynamics), and the intensity of bands corresponding to protected mRNAs was quantified with ImageQuant image analysis software (Molecular Dynamics) using L32 as a reference gene.
###end p 27
###begin title 28
Statistical analysis.
###end title 28
###begin p 29
###xml 96 97 94 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 153 154 151 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Data are expressed as the means +/- SD. Statistical significance was determined using Student's t test, and differences were considered significant when P < 0.05.
###end p 29
###begin title 30
RESULTS
###end title 30
###begin title 31
###xml 100 101 97 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice induced to express TGF-beta in the islets show increased islet infiltration by autoreactive CD8+ T-cells activated in the periphery.
###end title 31
###begin p 32
###xml 807 808 774 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 801 808 768 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 1060 1061 1021 1022 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1100 1102 1061 1063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 1160 1162 1121 1123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 1163 1165 1124 1126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 1271 1272 1229 1230 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1398 1399 1353 1354 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1583 1584 1532 1533 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1763 1764 1712 1713 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1853 1854 1799 1800 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1847 1854 1793 1800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 1885 1886 1831 1832 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 81 85 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 86 90 <span type="species:ncbi:10090">mice</span>
###xml 106 110 <span type="species:ncbi:10090">mice</span>
###xml 414 418 <span type="species:ncbi:10090">mice</span>
###xml 435 439 <span type="species:ncbi:10090">mice</span>
###xml 468 472 <span type="species:ncbi:10090">mice</span>
###xml 492 496 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 606 610 <span type="species:ncbi:10090">mice</span>
###xml 746 750 <span type="species:ncbi:10090">mice</span>
###xml 846 850 <span type="species:ncbi:10090">mice</span>
###xml 1003 1007 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 1024 1028 <span type="species:ncbi:10090">mice</span>
###xml 1310 1314 <span type="species:ncbi:10090">mice</span>
###xml 1334 1338 <span type="species:ncbi:10090">mice</span>
###xml 1489 1493 <span type="species:ncbi:10090">mice</span>
###xml 1665 1669 <span type="species:ncbi:10090">mice</span>
###xml 1841 1845 <span type="species:ncbi:10090">mice</span>
###xml 2052 2056 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 2106 2110 <span type="species:ncbi:10090">mice</span>
We investigated the effect of TGF-beta expression locally in the pancreas of RIP-LCMV mice. BALB/c RIP-NP mice were generated in the tetracycline-dependent TGF-beta gene transcription system (TTA/TGF-beta), which allows for TGF-beta expression in the islets to be turned on and off at will. TGF-beta transcription was induced by removing doxycycline from the diet of double-transgenic TTA/TGF-beta x BALB/c RIP-NP mice (RIP-NP.TGFbeta mice). Then, 1 week later, these mice were infected with LCMV and analyzed 7 days later for TGF-beta expression in the islets by immunohistochemistry. Only RIP-NP.TGFbeta mice that were fed a doxycycline-free diet expressed the TGF-beta protein selectively in the islets, whereas doxycycline-fed RIP-NP.TGFbeta mice and their transgene-negative littermates did not (Fig. 1A). The islets of naive RIP-NP.TGFbeta mice fed a doxycycline-free diet showed no sign of infiltration (data not shown). On the other hand and surprisingly, TGF-beta expression in the pancreas of LCMV-infected RIP-NP mice induced the accumulation of CD8+ T-cells with diabetogenic properties (15), reflecting their previous activation in the periphery (17,18). These observations indicate an enhancing effect of TGF-beta on the survival of previously activated CD8+ T-cells. Furthermore, whereas RIP-NP mice and RIP-NP.TGFbeta mice fed doxycycline displayed comparable infiltration, with CD8+ T-cells present mostly around the periphery of the islets, the islets of RIP-NP.TGF-beta mice induced to express TGF-beta by removal of doxycycline were massively infiltrated with CD8+ T-cells. In addition, tetramer staining of lymphocytes from pooled pancreata of mice fed a doxycycline-free diet revealed the presence of twice as many nucleoprotein-specific CD8+ T-cells in the pancreas of TGF-beta-expressing compared with control RIP-NP mice (Fig. 1B). Of note, accumulation of CD8+ T effectors was seen only in the pancreas, where TGF-beta was expressed, but not in the spleen and pancreatic draining lymph node. Accordingly, systemic immunity to LCMV was identical in TGF-beta-expressing and control mice, which cleared the infection with similar kinetics (data not shown).
###end p 32
###begin title 33
###xml 71 72 68 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
TGF-beta promotes the survival of previously activated autoreactive CD8+ T-cells by decreasing their apoptosis.
###end title 33
###begin p 34
###xml 334 335 328 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 328 335 322 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic></xref>
###xml 413 414 404 405 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 692 693 680 681 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 743 744 731 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 737 744 725 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic></xref>
###xml 789 790 777 778 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1038 1039 1017 1018 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1160 1161 1139 1140 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1380 1381 1353 1354 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1555 1556 1528 1529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1549 1556 1522 1529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>B</italic></xref>
###xml 1559 1561 1532 1534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r25">25</xref>
###xml 1742 1743 1712 1713 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1759 1760 1729 1730 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1753 1760 1723 1730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>C</italic></xref>
###xml 182 186 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 280 284 <span type="species:ncbi:10090">mice</span>
###xml 538 542 <span type="species:ncbi:10090">mice</span>
###xml 849 853 <span type="species:ncbi:10090">mice</span>
###xml 1404 1408 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 1423 1427 <span type="species:ncbi:10090">mice</span>
###xml 1458 1462 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
To identify the cause for the increased number of autoreactive effectors in TGF-beta-expressing islets, we assessed apoptosis of these cells by TUNEL. At 7 days after infection with LCMV, the number of TUNEL-positive cells appeared smaller in infiltrated islets of RIP-NP.TGFbeta mice than in those of their RIP-NP littermates (Fig. 2A), which indicated that TGF-beta reduced apoptosis of previously activated CD8+ T-cell effectors. However, it was difficult to compare apoptosis quantitatively in the islets of RIP-NP.TGFbeta and RIP-NP mice, which differed in the extent of infiltration. Cell suspensions were thus prepared from pooled pancreata 7 days after infection and stained with H2-ld/NP118 tetramers and annexin V. As shown in Fig. 2A, the frequency of nucleoprotein-specific CD8+ T-cells expressing annexin V was higher in RIP-NP.TGFbeta mice induced to express TGF-beta in the islets by doxycycline removal compared with control RIP-NP littermates. Therefore, expression of TGF-beta in the vicinity of previously activated CD8+ T-cells led to their enhanced survival and subsequent accumulation at the effector site. These results indicate that CD8+ T-cell effectors that have previously responded to antigenic stimulation are enhanced rather than suppressed by TGF-beta. Accordingly, TGF-beta did not hinder but rather enhanced the capacity of antigen-experienced CD8+ T-cells obtained from LCMV-immune BALB/c mice to proliferate in response to LCMV in vitro and did not prevent upregulation of the cell cycle proteins cyclin D and A2 (Fig. 2B) (25). In fact, binding of annexin V to these cells was significantly reduced in the presence of TGF-beta, indicating an antiapoptotic effect of this cytokine on antigen-experienced CD8+ T-cells (Fig. 2C).
###end p 34
###begin title 35
Absence of TGF-beta receptor signaling in T-cells has opposing effects on autoimmune diabetes depending on the effector mechanism.
###end title 35
###begin p 36
###xml 110 111 107 108 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 237 238 231 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 344 345 338 339 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 476 477 470 471 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 564 565 558 559 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 877 878 859 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 871 878 853 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 1017 1018 996 997 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1011 1018 990 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>B</italic></xref>
###xml 1144 1145 1120 1121 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1203 1204 1179 1180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1197 1204 1173 1180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 1249 1250 1225 1226 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1586 1587 1553 1554 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1648 1649 1612 1613 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1642 1649 1606 1613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>B</italic></xref>
###xml 1694 1695 1655 1656 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1792 1793 1750 1751 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1838 1839 1796 1797 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1832 1839 1790 1797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>C</italic></xref>
###xml 1905 1906 1863 1864 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1899 1906 1857 1864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>D</italic></xref>
###xml 2022 2023 1980 1981 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2252 2253 2201 2202 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 534 538 <span type="species:ncbi:10090">mice</span>
###xml 643 647 <span type="species:ncbi:10090">mice</span>
###xml 664 668 <span type="species:ncbi:10090">mice</span>
###xml 865 869 <span type="species:ncbi:10090">mice</span>
###xml 1005 1009 <span type="species:ncbi:10090">mice</span>
###xml 1127 1131 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 1181 1185 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 1424 1428 <span type="species:ncbi:10090">mice</span>
###xml 1636 1640 <span type="species:ncbi:10090">mice</span>
###xml 1927 1931 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
These observations pointed to opposite roles of TGF-beta on naive compared with antigen-experienced/memory CD8+ T-cells. We thus evaluated the impact of TGF-beta in two type 1 diabetes models that differed in terms of requirement for CD8+ T-cell activation: the fast-onset C57BL/6 RIP-GP model, which is caused by robust activation of naive CD8+ T-cells, and the slow-onset C57BL/6 RIP-NP model, which results from accumulation and activation of antigen-experienced/memory CD8+ T-cells. We generated C57BL/6 RIP-GP and C57BL/6 RIP-NP mice in which autoreactive CD8+ T-cells are unable to signal through the TGF-beta receptor by crossing these mice with dnTGFbetaR mice, which express a dominant-negative TGF-beta receptor specifically in T-cells. Although "naive-dependent" fast-onset diabetes was dramatically accelerated in RIP-GP.dnTGFbetaR compared with RIP-GP mice (Fig. 3A), incidence of "memory-dependent" slow-onset diabetes was reduced more than twofold in RIP-NP.dnTGFbetaR compared with RIP-NP mice (Fig. 3B). Absence of TGF-beta receptor signaling in T-cells resulted in a threefold increase in the total number of LCMV-specific CD8+ T-cells in the spleen 7 days after LCMV infection (Fig. 4A). Thus, impaired responsiveness of naive CD8+ T-cells to TGF-beta enhanced their activation and expansion, which likely accounted for accelerated diabetes in the RIP-GP.dnTGFbetaR group and in the few RIP-NP.dnTGFbetaR mice that developed disease (between 1 and 2 weeks after infection in this otherwise slow-onset model). However, by day 30 the overall number of GP33-specific CD8+ T-cells was similar in wild-type and dnTGFbetaR mice (Fig. 4B), indicating that TGF-beta-nonresponsive CD8+ T-cells had undergone increased contraction. Furthermore, TGF-beta receptor-deficient memory CD8+ T-cells were more prone to apoptosis (Fig. 4C) and completely defective in terms of secondary expansion (Fig. 4D) when stimulated by LCMV-infected antigen-presenting cells in vitro. Thus, impaired responsiveness of activated CD8+ T-cells to TGF-beta diminished their survival and maintenance as memory cells, which likely accounted for reduced slow-onset diabetes in the RIP-NP.dnTGFbetaR system. This indicates that TGF-beta prevents activation of naive CD8+ T-cells, which cause fast-onset diabetes, but promotes the survival and accumulation of antigen-experienced cells, which cause slow-onset disease.
###end p 36
###begin title 37
###xml 29 30 26 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 130 131 127 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
TGF-beta suppresses naive CD8+ T-cell activation and enhances the survival and effector function of antigen-experienced/memory CD8+ T-cells.
###end title 37
###begin p 38
###xml 204 205 201 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 314 315 311 312 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 434 435 428 429 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 555 556 538 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 561 562 544 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 549 562 532 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>A</italic> and <italic>B</italic></xref>
###xml 712 713 692 693 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 799 800 779 780 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 937 938 914 915 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 943 944 920 921 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 931 944 908 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>C</italic> and <italic>D</italic></xref>
###xml 1005 1007 982 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 1115 1117 1092 1094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 1178 1179 1152 1153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1172 1179 1146 1153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>E</italic></xref>
###xml 1278 1279 1249 1250 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1330 1331 1301 1302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1324 1331 1295 1302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>C</italic></xref>
###xml 1359 1360 1330 1331 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1376 1377 1347 1348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1370 1377 1341 1348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>C</italic></xref>
###xml 1636 1637 1603 1604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1642 1643 1609 1610 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1630 1643 1597 1610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>A</italic> and <italic>B</italic></xref>
###xml 1800 1801 1764 1765 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1794 1801 1758 1765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>E</italic></xref>
###xml 1921 1922 1882 1883 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
Based on these observations, we investigated in further detail the differential effect of TGF-beta on activation, proliferation, and effector function of naive compared with antigen-experienced/memory CD8+ T-cells. This was addressed by comparing the response mounted in vitro by naive and memory GP33-specific CD8+ T-cells stimulated with GP33-loaded dendritic cells in the presence or absence of TGF-beta. We observed that naive CD8+ T-cells lost their capacity to produce gamma-interferon (IFN-gamma) when stimulated in the presence of TGF-beta (Fig. 5A and B). Interestingly, IL-17 production by these cells was, on the other hand, increased, though modestly, indicating that TGF-beta favored a switch of CD8+ T-cells from a Th1-like (Tc1) to a Th17-like phenotype (Tc17). Furthermore, naive CD8+ T-cells stimulated in the presence of TGF-beta showed impaired proliferation associated with upregulation of cyclin D but not A2 (Fig. 5C and D), which indicated a block in the S phase of the cell cycle (26). In addition, binding of annexin V and expression of the proapoptotic molecule programmed death 1 (PD-1) (27) on stimulated naive cells was increased by TGF-beta (Fig. 5E). In marked contrast, TGF-beta did not affect proliferation of stimulated GP33-specific memory CD8+ T-cells, consistent with our observation in Fig. 2C using polyclonal memory CD8+ T-cells (Fig. 5C). Furthermore, although IL-17 production was increased in GP33-specific memory cells (as observed in naive GP33-specific cells), the overall increase was greater in these compared with naive cells and not accompanied by a loss in IFN-gamma production (Fig. 5A and B). In addition, as opposed to naive cells, memory cells stimulated in the presence of TGF-beta showed decreased apoptosis and did not upregulate PD-1 (Fig. 5E). These observations indicate that TGF-beta not only increases the survival of activated antigen-experienced/memory CD8+ T-cells but also enhances their capacity to produce IL-17 in the presence of IFN-gamma by inducing an incomplete switch from Tc1 to Tc17.
###end p 38
###begin title 39
DISCUSSION
###end title 39
###begin p 40
###xml 195 196 189 190 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 420 421 411 412 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 548 549 536 537 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 648 649 633 634 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1100 1101 1075 1076 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1218 1219 1190 1191 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1238 1240 1210 1212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r28">28</xref>
###xml 1241 1243 1213 1215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r29">29</xref>
We observed that TGF-beta expression in the vicinity of already activated autoreactive T-cells promotes their survival and accumulation, which highlighted a differential effect of TGF-beta on CD8+ T-cell responses derived from naive versus antigen-experienced/memory progenitors. Our results show that the role of TGF-beta in type 1 diabetes is highly dependent on the differentiation state and activation history of CD8+ T-cells. We found that TGF-beta inhibits activation and proliferation of naive but not antigen-experienced/memory effector CD8+ T-cells. Furthermore, TGF-beta exerts an antiapoptotic effect on activated antigen-experienced CD8+ T-cells and thus enhances their survival. In addition, TGF-beta promotes a switch from a Tc1 to a Tc17 phenotype, which is incomplete in stimulated memory cells, resulting in both IFN-gamma and IL-17 production by these cells. These results correlate precisely with our observation that lack of a functional TGF-beta receptor on T-cells has enhancing and dampening effects on diabetes induced by activation of naive and antigen-experienced/memory CD8+ T-cells, respectively. Previous work also indicates divergent effects of TGF-beta on naive versus differentiated CD4+ T-cells in vitro (28,29).
###end p 40
###begin p 41
###xml 200 202 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 203 205 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 206 208 197 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 351 353 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 618 619 600 601 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 962 964 944 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 1751 1753 1721 1723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 1754 1756 1724 1726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 47 51 <span type="species:ncbi:10090">mice</span>
###xml 114 119 <span type="species:ncbi:10090">mouse</span>
###xml 256 260 <span type="species:ncbi:10090">mice</span>
###xml 643 647 <span type="species:ncbi:10090">mice</span>
###xml 877 881 <span type="species:ncbi:10090">mice</span>
###xml 987 991 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 1745 1749 <span type="species:ncbi:10090">mice</span>
Our results using TTA/TGF-beta x BALB/c RIP-NP mice (RIP-NP.TGFbeta) stand in some contrast to studies in the NOD mouse, in which constitutive expression of TGF-beta in the islets prevented diabetes (12,13,30). Similarly, in studies using TTA/TGF-beta NOD mice, where no fibrosis was observed, TGF-beta exerted a protective effect on type 1 diabetes (14). An important factor might thus be whether priming of autoreactive T-cells occurs in the periphery or within the islets of Langerhans. Based on our present observations, one would expect TGF-beta to have a protective effect at locations where priming of naive CD8+ T-cells occurs. In NOD mice, it is possible that a significant proportion of priming occurs locally in the islets of Langerhans or in the pancreatic draining lymph nodes, where the earliest signs of immunopathogenesis are seen. Previous observations in NOD mice show that priming in the islets and the lymph nodes are not necessarily linked (31). In contrast, in RIP-LCMV models for fast-onset diabetes (BALB/c RIP-NP and C57BL/6 RIP-GP), activation of autoreactive T-cells occurs in the periphery in lymphoid organs and at sites of viral replication. Furthermore, in these models, as opposed to the slow-onset C57BL/6 RIP-NP model, maintenance of antigen-experienced/memory cells over time is not necessary for attack and destruction of beta-cells. Thus, the antiapoptotic effect of TGF-beta on effector T-cells will outweigh its suppressive function on naive precursors locally in the islets. This fits well with the previous observation that TGF-beta does not protect against already differentiated diabetogenic T-cells, as evidenced by similar destruction of TGF-beta-expressing and control islet transplants in diabetic mice (13,15). Thus, our results suggest that TGF-beta will have different effects in vivo depending on where priming of autoreactive T-cells occurs.
###end p 41
###begin p 42
###xml 129 130 126 127 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 234 235 228 229 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 462 463 453 454 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 467 468 458 459 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 529 531 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r32">32</xref>
###xml 639 640 624 625 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 644 645 629 630 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 680 682 665 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 803 804 782 783 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 808 809 787 788 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 880 882 859 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 1017 1019 993 995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 1055 1057 1031 1033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 1350 1351 1317 1318 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1355 1356 1322 1323 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1456 1458 1423 1425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 1459 1461 1426 1428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r33">33</xref>
###xml 1462 1464 1429 1431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r35">35</xref>
###xml 1493 1495 1460 1462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r36">36</xref>
###xml 1537 1538 1504 1505 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1564 1565 1531 1532 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1689 1690 1653 1654 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1837 1838 1801 1802 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1971 1972 1929 1930 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2185 2186 2137 2138 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 453 458 <span type="species:ncbi:9606">human</span>
###xml 541 546 <span type="species:ncbi:10090">mouse</span>
###xml 933 938 <span type="species:ncbi:10090">mouse</span>
We found that in the absence of TGF-beta receptor signaling in T-cells, priming and expansion of naive antiviral/autoreactive CD8+ T-cells are enhanced in vivo. Although this might be caused by a direct effect of TGF-beta on naive CD8+ T-cells, it is also possible that absence of TGF-beta receptor signaling decreases the function or induction of regulatory T-cells, which thereby enables enhanced naive T-cell activation. Previous work has shown that human CD4+CD25+ regulatory T-cells can be expanded in vitro using TGF-beta (32). In the mouse, TGF-beta was shown to prevent spontaneous type 1 diabetes by promoting the expansion of CD4+CD25+ regulatory T-cells in the islets (14). Furthermore, it was recently shown that expression of TGF-beta selectively in beta-cells promotes the induction of CD4+CD25+ regulatory T-cells that protect from virally induced type 1 diabetes (30). However, expansion of regulatory T-cells in the mouse in vivo occurred only when TGF-beta was expressed early, starting from birth (14), or constitutively in the islets (30). Furthermore, as discussed above, the effect of TGF-beta might rely on where T-cell priming occurs in vivo. This further underscores our observation that the effect of TGF-beta on T-cells depends on their activation/differentiation state. Of note, the role of TGF-beta in the function of CD4+CD25+ regulatory T-cells is not clear, with some work demonstrating an important role for this cytokine (10,33-35), and other no involvement (36). In any case, we observed that naive CD8+ T-cells isolated from CD4+ T-cells and stimulated in vitro in the presence of TGF-beta show impaired activation and proliferation, indicating that CD4+ regulatory T-cells are not involved in the process. Furthermore, we observed no upregulation of Foxp3 or decrease in CD127 expression on naive CD8+ T-cells stimulated in the presence of TGF-beta (data not shown), making it unlikely that TGF-beta induced the differentiation of CD8+ regulatory T-cells. Thus, impaired TGF-beta receptor signaling in T-cells enhanced activation of naive T-cells and impaired the survival of memory T-cells in vivo most likely as a direct effect of TGF-beta on CD8+ T-cell effectors. As a consequence, fast-onset diabetes, which depends on activation of naive T-cells, was accelerated, whereas slow-onset diabetes, which requires maintenance of antigen-experienced/memory effectors, was reduced.
###end p 42
###begin p 43
###xml 288 289 282 283 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 514 516 505 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r37">37</xref>
###xml 517 519 508 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r38">38</xref>
###xml 609 610 597 598 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 827 828 812 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 829 830 814 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 831 832 816 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 980 981 962 963 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1118 1120 1100 1102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 1121 1123 1103 1105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r39">39</xref>
###xml 1124 1126 1106 1108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r42">42</xref>
###xml 1240 1241 1219 1220 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1345 1346 1324 1325 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1554 1555 1527 1528 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 475 479 <span type="species:ncbi:10090">mice</span>
###xml 1082 1086 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
Our results indicate that the importance of TGF-beta for the survival of antigen-experienced/memory T-cells and their subsequent effect on type 1 diabetes is attributable at least partially to the antiapoptotic properties of this cytokine. We observed that TGF-beta receptor-deficient CD8+ T-cells are more prone to apoptosis and harbor impaired capacity of secondary expansion. In this respect, previous work by others indicates that T-cells derived from TGF-beta-deficient mice show enhanced apoptosis in vitro (37,38). In vitro, we found that TGF-beta diminishes annexin V binding and thus apoptosis of CD8+ T-cell effectors derived from memory but not naive precursors. Accordingly, TGF-beta was reported to have potent antiapoptotic effects in vitro, possibly as a result of inhibition of Fas ligand and c-Myc expression (4,5,7). Although we did not assess Fas ligand or c-Myc expression on T-cells stimulated in vitro, we found that TGF-beta induced naive but not memory CD8+ T-cells to upregulate PD-1, which is a proapoptotic molecule that controls T-cell responses in both LCMV infection and type 1 diabetes (27,39-42). In vivo, we found that expression of TGF-beta locally in the islets results in accumulation of autoreactive CD8+ T-cell effectors, which exhibited reduced apoptosis. Importantly, the frequency of antigen-specific CD8+ T-cells was enhanced only in the vicinity of TGF-beta in the islets, but not in the spleen or pancreatic draining lymph node. In other words, absence of TGF-beta expression in the periphery enabled naive CD8+ T-cell activation to occur normally in the spleen and pancreatic draining lymph node, whereas TGF-beta expressed locally in the islets exerted its antiapoptotic effect on subsequently activated effectors infiltrating the pancreas.
###end p 43
###begin p 44
###xml 159 160 156 157 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 284 285 278 279 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 361 363 355 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r43">43</xref>
###xml 475 477 465 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r44">44</xref>
###xml 478 480 468 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r45">45</xref>
###xml 615 617 605 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r43">43</xref>
###xml 733 735 723 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r46">46</xref>
###xml 761 762 751 752 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 846 848 836 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r47">47</xref>
###xml 1096 1098 1086 1088 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r48">48</xref>
###xml 1329 1330 1316 1317 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1586 1587 1560 1561 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1022 1026 <span type="species:ncbi:10090">mice</span>
Based on our observations, another important parameter accounting for the differential effect of TGF-beta on naive compared with antigen-experienced/memory CD8+ T-cells might be their capacity to produce IL-17. It was recently reported that TGF-beta can induce IL-17 production by CD4+ T-cells when acting in combination with the proinflammatory cytokine IL-6 (43). Such Th17 cells produce IL-17 but not IFN-gamma, which actually inhibits their differentiation and function (44,45). Th17 cells and IL-17 production might play a crucial role in mediating pathology in autoimmune diseases such as multiple sclerosis (43). In fact, IL-17 is an important regulator of inflammation and is elevated in a number of inflammatory conditions (46). IL-17 production by CD8+ T-cells (Tc17) has also been described and shown to harbor colitogenic properties (47). Although the role of Th17/Tc17 cells and IL-17 in type 1 diabetes is not understood, a recent report indicates that normoglycemia can be restored but not prevented in NOD mice through inhibition of IL-17 production after antigen administration (48). Therefore, although IL-17 may not initiate beta-cell destruction, it may contribute to pathology once autoimmunity has been induced. We do not know whether IL-17 production plays a role in the pathological function of memory CD8+ T-cells stimulated in the presence of TGF-beta. However, we observed that these cells, as opposed to naive cells, are also capable of producing IFN-gamma and thus likely to cause beta-cell destruction. It is thus possible that TGF-beta provides memory CD8+ T-cells with enhanced capacity to exacerbate beta-cell destruction once they have initiated it. On the other hand, naive cells stimulated with TGF-beta, despite their capacity to produce IL-17, are not capable of IFN-gamma production and might thus lack essential properties to be pathological.
###end p 44
###begin p 45
###xml 682 683 673 674 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 756 758 747 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r49">49</xref>
###xml 1026 1027 1017 1018 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1200 1201 1188 1189 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 596 600 <span type="species:ncbi:10090">mice</span>
###xml 800 804 <span type="species:ncbi:10090">mice</span>
###xml 931 935 <span type="species:ncbi:10090">mice</span>
###xml 1039 1043 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
Our results also have important implications for understanding the factors required to optimize antiviral vaccines, where the objective is to generate and maintain an optimal number of memory T-cells rather than inducing a strong primary response to the vaccine. Based on our observations, TGF-beta, which is normally thought of as an immune dampening factor, might actually be beneficial for expanding and maintaining such antiviral memory T-cells. On the other hand, blockade of TGF-beta might be beneficial in situations where boosting the priming of effector T-cells is desired. For example, mice deficient in TGF-beta receptor signaling generate an increased tumor-specific CD8+ T-cell response that leads to tumor eradication and long-term survival (49). Although it is not known whether these mice generate long-term memory, for example after tumor rechallenge, they nonetheless show improved survival compared with control mice after initial tumor vaccination. In our studies, reduced secondary expansion of memory CD8+ T-cells to LCMV was observed in the absence of TGF-beta receptor signaling, but viral clearance occurred normally, probably because of the massive expansion of effector CD8+ T-cells that occurred during the primary response. Thus, blockade of TGF-beta may still constitute a strong therapeutic strategy for generating antitumor immunity, even if long-term memory generation is impaired.
###end p 45
###begin p 46
In conclusion, our studies have implications for the therapeutic use of TGF-beta. In autoimmune diseases such as type 1 diabetes, TGF-beta may not always be inhibitory and may actually act to enhance the survival of autoreactive T-cells, depending on their differentiation state. Therefore, it is possible that TGF-beta therapy initiated during the early stages of autoimmune disease is beneficial by suppressing activation of naive autoreactive T-cells or inducing regulatory T-cells, whereas late initiation of treatment may be detrimental because most autoreactive T-cells are already fully differentiated at this point. On the other hand, blockade of TGF-beta to boost immune responses, for example after tumor cell vaccination, may enhance the priming of T-cells but could have negative implications for the generation of long-lived memory T-cells. Thus, for systemic treatments involving the administration or blockade of TGF-beta, one will have to consider the precise balance of naive and effector/memory T-cells within the targeted population.
###end p 46
###begin p 47
This work was supported by National Institutes of Health grants AI44451, DK51091, and U-19 AI 51973; a Juvenile Diabetes Research Foundation (JDRF) research grant (to M.G.vH.); grants from the American Diabetes Association and the National Institute of Diabetes and Digestive and Kidney Diseases (to R.A.F.); and two JDRF postdoctoral fellowships (to A.E.J. and C.M.F.). R.A.F. is an investigator of the Howard Hughes Medical Institute.
###end p 47
###begin p 48
###xml 106 111 <span type="species:ncbi:10090">mouse</span>
We thank Dr. Urs Christen and Antje Rhode for the generation of MHC class I tetramers, Malina McClure for mouse colony maintenance, and Priscilla Colby for administrative assistance.
###end p 48
###begin title 49
REFERENCES
###end title 49
###begin p 50
###xml 100 101 97 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 402 403 390 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 638 639 623 624 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 695 705 677 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink">top panels</italic>
###xml 720 733 702 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bottom panels</italic>
###xml 773 774 755 756 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 966 967 948 949 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 158 162 <span type="species:ncbi:10090">mice</span>
###xml 195 199 <span type="species:ncbi:10090">mice</span>
###xml 271 275 <span type="species:ncbi:10090">mice</span>
###xml 493 497 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 886 890 <span type="species:ncbi:10090">mice</span>
Mice induced to express TGF-beta in the islets show increased islet infiltration by autoreactive CD8+ T-cells activated in the periphery. TTA/TGF-beta BALB/c mice were crossed with BALB/c RIP-NP mice to generate double-transgenic RIP-NP.TGFbeta offspring. RIP-NP.TGFbeta mice and their single-transgenic RIP-NP littermates were fed a diet containing doxycycline (dox) during gestation and after birth. A: Doxycycline was either maintained or removed from the diet 7 days before infection with LCMV, and pancreata were harvested 7 days later (day 14 after doxycycline removal). Tissue sections were analyzed for TGF-beta production and CD8+ T-cell infiltration after staining with anti-TGF-beta (top panels) or anti-CD8 (bottom panels) and counterstaining with hematoxylin. B: Single-cell suspensions were prepared from the pancreas, spleen, or pancreatic draining lymph nodes (PDLN) of mice fed a doxycycline-free diet. The frequency of NP118-specific/responsive CD8+ T-cells was evaluated in pooled pancreata (three to four) by tetramer staining and in the spleen and pancreatic draining lymph nodes by flow cytometry after stimulation with NP118 ex vivo. (Please see  for a high-quality digital representation of this figure.)
###end p 50
###begin p 51
###xml 71 72 68 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 112 113 109 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 232 242 229 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">top panels</italic>
###xml 367 368 364 365 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 400 413 397 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bottom panels</italic>
###xml 470 471 467 468 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 504 505 501 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 510 511 507 508 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 820 829 814 823 <italic xmlns:xlink="http://www.w3.org/1999/xlink">top panel</italic>
###xml 911 923 905 917 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bottom panel</italic>
###xml 926 927 920 921 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 932 933 926 927 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1280 1281 1271 1272 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 192 196 <span type="species:ncbi:10090">mice</span>
###xml 341 345 <span type="species:ncbi:10090">mice</span>
###xml 553 557 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 572 576 <span type="species:ncbi:10090">mice</span>
###xml 615 619 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 975 979 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 994 998 <span type="species:ncbi:10090">mice</span>
###xml 1017 1021 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
TGF-beta promotes the survival of previously activated autoreactive CD8+ T-cells by decreasing their apoptosis. A: Apoptosis was evaluated by TUNEL in pancreatic tissue sections obtained from mice fed a doxycycline (dox)-free diet (top panels). Cell suspensions were prepared from the pooled pancreatic draining lymph nodes of three to four mice and stained with H2-ld/NP118 tetramers and annexin V (bottom panels). Histograms show the frequency of tetramer-positive CD8+ T-cells stained with annexin V. B: CD8+ T-cells were purified from the spleen of LCMV-immune BALB/c mice, labeled with CFSE, and cultured with LCMV-infected, irradiated, antigen-presenting cells in the presence or absence of 3 ng/ml rhTGF-beta1. Cell proliferation was assessed by measuring CFSE dilution by flow cytometry after 6 days in culture (top panel) or cell cycle protein RNA was quantitated by RNase protection assay after 24 h (bottom panel). C: CD8+ T-cells were isolated from the spleen of LCMV-immune BALB/c mice and cultured with LCMV-infected, irradiated, antigen-presenting cells in the presence or absence of 3 ng/ml rhTGF-beta1. After 1 and 3 days in culture, T-cells were analyzed for apoptosis by flow cytometry after staining with annexin V. Data represents the average frequency of CD8+ T-cells stained with annexin V +/- SD from three independent experiments. (Please see  for a high-quality digital representation of this figure.)
###end p 51
###begin p 52
###xml 274 275 265 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 302 303 290 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 158 162 <span type="species:ncbi:10090">mice</span>
###xml 277 281 <span type="species:ncbi:10090">mice</span>
###xml 305 309 <span type="species:ncbi:10090">mice</span>
###xml 387 391 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 458 462 <span type="species:ncbi:10090">Mice</span>
Absence of TGF-beta receptor signaling in T-cells has opposite effects on virally induced autoimmune diabetes depending on the effector mechanism. dnTGFbetaR mice were crossed onto fast-onset diabetes RIP-GP or slow-onset diabetes RIP-NP lines. Groups of RIP-GP.dnTGFbetaR (A) mice, RIP-NP.dnTGFbetaR (B) mice, and their single transgenic RIP-GP or RIP-NP littermates were infected with LCMV, and diabetes incidence was monitored by measuring blood glucose. Mice were considered diabetic when blood glucose exceeded 300 mg/dl.
###end p 52
###begin p 53
###xml 72 73 69 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 226 227 220 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 232 233 226 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 291 292 285 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 310 311 304 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 521 522 511 512 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 600 601 590 591 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 726 727 680 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1022 1023 973 974 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1089 1090 1038 1039 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 151 155 <span type="species:ncbi:10090">mice</span>
###xml 220 224 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 235 239 <span type="species:ncbi:10090">Mice</span>
###xml 650 654 <span type="species:ncbi:10090">mice</span>
###xml 772 776 <span type="species:ncbi:10090">mice</span>
###xml 837 841 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 1073 1077 <span type="species:ncbi:10090">mice</span>
Absence of TGF-beta receptor signaling in T-cells enhances antiviral CD8+ T-cell responses at the acute phase but reduces memory responses. dnTGFbetaR mice and their wild-type (WT) C57BL/6 littermates were infected with LCMV. A and B: Mice were killed and spleens harvested on day 7 (peak) (A) or 28 (memory) (B) postinfection. The frequency of IFN-gamma-producing cells (measured by flow cytometry after stimulation with GP33) was multiplied by the total number of splenocytes to obtain the number of GP33-responsive CD8+ T-cells per spleen. Data represents the average number of GP33-responsive CD8+ T-cells per spleen +/- SD from three individual mice per group. blacksquare, square, filled, wild-type; square, dnTGFbetaR. C: Splenocytes were harvested from dnTGFbetaR mice 28 days postinfection, labeled with CFSE, and cultured with LCMV-infected, irradiated, antigen-presenting cells. Cells were harvested 2 or 3 days later and stained for expression of CD8 and annexin V. Data represents the average frequency of CD8+ T-cells stained with annexin V +/- SD from three mice per group. D: Alternatively, cells were harvested 6 days later and analyzed for IFN-gamma production by flow cytometry after stimulation with GP33. Representative fluorescence-activated cell sorting plots are shown.
###end p 53
###begin p 54
###xml 29 30 26 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 130 131 127 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 144 145 141 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 366 367 360 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 372 373 366 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 525 526 515 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 540 541 530 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 546 547 536 537 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 630 631 614 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 816 826 800 810 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left panel</italic>
###xml 839 850 823 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right panel</italic>
###xml 855 856 839 840 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1006 1007 985 986 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1032 1033 1011 1012 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1131 1132 1110 1111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1125 1132 1104 1111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>B</italic></xref>
###xml 1134 1135 1113 1114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1290 1291 1269 1270 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1324 1334 1303 1313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left panel</italic>
###xml 1356 1367 1335 1346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right panel</italic>
###xml 200 204 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 220 224 <span type="species:ncbi:10090">mice</span>
###xml 614 618 <span type="species:ncbi:10090">mice</span>
###xml 990 994 <span type="species:ncbi:10090">mice</span>
###xml 1398 1402 <span type="species:ncbi:10090">mice</span>
TGF-beta suppresses naive CD8+ T-cell activation and enhances the survival and effector function of antigen-experienced/memory CD8+ T-cells. CD8+ T-cells were purified from the spleen of naive P14 or LCMV-immune C57BL/6 mice, labeled with CFSE, cultured with GP33-loaded dendritic cells in the presence or absence of 3 ng/ml rhTGF-beta1, and harvested 2 days later. A and B: Cells were analyzed for IFN-gamma and IL-17 production by flow cytometry after stimulation with GP33. Data represents the average frequency of naive (A) and memory (B) CD8+ T-cells producing IFN-gamma or IL-17 +/- SD from three individual mice per group. C: Cell proliferation was assessed by measuring CFSE dilution by flow cytometry. Representative fluorescence-activated cell sorting plots are shown. Values show the percentage of naive (left panel) or memory (right panel) CD8+ T-cells that have undergone at least one division on stimulation in the presence or absence of TGF-beta +/- SD from three individual mice per group. D: Naive GP33-specific CD8+ T-cells were analyzed for cell cycle protein RNA by RNase protection assay as described in Fig. 2B. E: Cells were analyzed by flow cytometry for apoptosis after staining with annexin V or for expression of PD-1. Data represents the average frequency of CD8+ T-cells stained with annexin V (left panel) or expressing PD-1 (right panel) +/- SD from three individual mice per group.
###end p 54

